New schemes

We actively follow the development of laboratory medicine as we want to produce clinically relevant EQA schemes to serve clinical laboratories and point-of-care sites. We launch new pilot studies on a regular basis and aim to increase our Labquality EQAS by Aurevia portfolio with 5-10 new EQA schemes every year.

See the latest schemes

Planned pilot studies for 2025

We are now proudly launching this year's first pilot studies, which will be conducted starting in March. Registration for these pilots is open and will close on 24 February 2025. More information and registration links are found below. The arranged pilots will be free of charge for a limited number of participants.

 This year, we also include a short survey in the pilot studies. By responding, you can give us important information on how we can make the EQA scheme better for you.

HPV-associated head and neck cancer

Labquality EQAS by Aurevia is introducing a new EQA scheme for Human papillomavirus (HPV) -associated head and neck cancer by arranging a pilot study free of charge for a limited number of participants.

Please register by 28 March 2025.

Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Labquality EQAS by Aurevia is introducing a new EQA scheme for bacterial vaginosis and vaginitis multiplex, nucleic acid detection by arranging a pilot study free of charge for a limited number of participants.

Registration is closed.

Gram stain, vaginal fluid

Labquality EQAS by Aurevia is introducing a new EQA scheme for Gram stain, vaginal fluid by arranging a pilot study free of charge for a limited number of participants.

Registration is closed.

Human Erythropoietin and Thrombopoietin

Labquality EQAS by Aurevia is introducing a new EQA scheme for human Erythropoietin and Thrombopoietin by arranging a pilot study free of charge for a limited number of participants.

Registration is closed.

Immunosuppressants

Labquality EQAS by Aurevia is introducing a new EQA scheme for immunosuppressive drugs including ciclosporin, tacrolimus, sirolimus and everolimus, by arranging a pilot study free of charge for a limited number of participants.

Registration is closed.

Heidi Berghäll

EQA Solutions Manager, R&D

heidi.berghall@aurevia.com

Kristel Virtanen

EQA Solutions Manager, IT

kristel.virtanen@aurevia.com

LQ_web news_EQA_EQA program 2025_1280x720

EQA Product Catalogue

Our external quality assessment service program includes more than 250 quality assessment schemes, covering all specialities of laboratory medicine. Furthermore, the program includes an extensive selection of services designed for medical laboratories and point-of-care testing sites.

golden-wave-pattern-with-word-gold-it (1)

Integrated EQA Service

Integrated EQA service is a completely new approach to external quality assessment. New programs integrate pre- and post-analytical EQA schemes into traditional analytical EQA providing support according to the ISO 15189 standard requirements.

doctor-performing-medical-research-lab (1)

New EQA Schemes

We actively follow the development of laboratory medicine as we want to produce clinically relevant EQA schemes to serve clinical laboratories and point-of-care sites. We launch new pilot studies on a regular basis and aim to increase our EQA portfolio with 5-10 new EQA schemes every year.

Digital External Quality Assessment Programs

Our digital EQA product line provides an advanced approach to external quality assessment. Digital EQA programs or virtual EQA programs use digital images, videos, virtual microscopy technology, and questionnaires as EQA samples.

Try the demo

Meet us at ESCMID 2025 in Vienna

We will be at the ESCMID 11-15 April 2025 in Vienna, Austria.

Aurevia appoints Jonna Pelanti as the new Head of EQA business area

We are delighted to announce the appointment of the new Head of the EQA business area Jonna Pelanti.

Meet us at BioMedica in Dublin

Meet us at the BioMedica exhibition at booth A18!

Aurevia appoints Ulrika Hammarström as the new Head of CRO business area

We are delighted to announce the appointment of the new Head of the CRO business area Ulrika Hammarström.

New schemes

Planned pilot studies for 2025

HPV-associated head and neck cancer

Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Gram stain, vaginal fluid

Human Erythropoietin and Thrombopoietin

Immunosuppressants

All planned pilot studies for 2025/2026

Recently performed pilot studies

Holotranscobalamin (HoloTC) and Methylmalonic Acid

Norovirus, antigen detection

Helicobacter pylori, nucleic acid detection

Maternal serum screening

Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection

Pipette control

Salivary Cortisol

Chemokine CXCL13

Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis

Faecal Elastase

Fungal infections, nucleic acid detection

Mycobacterium tuberculosis, rifampicin and isoniazid, nucleic acid detection

Adrenocorticothropic hormone ACTH and Cortisol

HSV1&2 / VZV / T. pallidum, nucleic acid detection

EQA for next-generation sequencing methods

Contact us for more information!

Heidi Berghäll

Kristel Virtanen

Explore our services

EQA Product Catalogue

Integrated EQA Service

New EQA Schemes

Digital External Quality Assessment Programs

Latest news

Meet us at ESCMID 2025 in Vienna

Aurevia appoints Jonna Pelanti as the new Head of EQA business area

Meet us at BioMedica in Dublin

Aurevia appoints Ulrika Hammarström as the new Head of CRO business area

Introducing the EQA Pilot Studies 2025